IL6 and COVID-19: It was declared to inhibit the release of IL-6 and IL-8 in vitro conditions.8 Respiratory decompensation caused by micro-thrombosis and abnormal immune responses might develop via activation of IL1B and IL6 in COVID-19.9 In this clinical status, enoxaparin might improve clinical condition both with its anticoagulant effect and preventing possible cytokine storm effect.